NCT06225440View on ClinicalTrials.gov

Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University Students

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

January 31, 2024

Conditions
Wellness, PsychologicalWell-Being, Psychological
Interventions
DIETARY_SUPPLEMENT

Levagen+® Palmitoylethanolamide (PEA)

Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.

DIETARY_SUPPLEMENT

Placebo

Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.

Trial Locations (1)

W1W 6UW

University of Westminster, London

All Listed Sponsors
collaborator

Gencor Pacific Group

INDUSTRY

lead

University of Westminster

OTHER